Fierce Pharma
Fierce Biotech
Fierce Healthcare
Fierce Life Sciences Events
Advertise
About Us
Biotech
Cell & Gene Therapy
Clinical Data
Venture Capital
Deals
Research
Medtech
Devices
Diagnostics
AI and Machine Learning
CRO
Special Reports
Trending Topics
Diabetes
Clinical Development
Biologics
Fierce 50
Special Report
Awards Gala
Resources
Fierce Events
Industry Events
Webinars
Podcasts
Whitepapers
Survey
Events
Subscribe
Trending T
Biotech
Cell & Gene Therapy
Clinical Data
Venture Capital
Deals
Research
Medtech
Devices
Diagnostics
AI and Machine Learning
CRO
Special Reports
Trending Topics
Diabetes
Clinical Development
Biologics
Fierce 50
Special Report
Awards Gala
Resources
Fierce Events
Industry Events
Webinars
Podcasts
Whitepapers
Survey
Events
Subscribe
Fierce Pharma
Fierce Biotech
Fierce Healthcare
Fierce Life Sciences Events
Advertise
About Us
RNA interference (RNAi)
Biotech
Arrowhead dips toes into obesity pond with 2 preclinical assets
After clearing out a clinical-stage cardiovascular candidate, Arrowhead is filling the blank space with two preclinical obesity assets.
Gabrielle Masson
Aug 14, 2024 3:50pm
Arrowhead RNAi med lowers triglycerides in phase 3
Jun 3, 2024 9:54am
Arrowhead's cholesterol drug hits the mark again in ph. 2 trial
May 28, 2024 9:13am
Arrowhead on target in lipid disorder as it pursues Ionis
Apr 8, 2024 9:37am
Arrowhead axes assets, but spares staff, to save $100M a year
Feb 7, 2024 6:01am
Alnylam, Biogen build noise in Alzheimer's with gene silencing
Oct 26, 2023 8:51am